SitesBLAST
Comparing Ga0059261_1376 FitnessBrowser__Korea:Ga0059261_1376 to proteins with known functional sites using BLASTp with E ≤ 0.001.
Or try Sites on a Tree, PaperBLAST, Conserved Domains, or compare to all protein structures
Found 20 (the maximum) hits to proteins with known functional sites (download)
Q1LK00 Tryptophan 2,3-dioxygenase; TDO; Tryptamin 2,3-dioxygenase; Tryptophan oxygenase; TO; TRPO; Tryptophan pyrrolase; Tryptophanase; EC 1.13.11.11 from Cupriavidus metallidurans (strain ATCC 43123 / DSM 2839 / NBRC 102507 / CH34) (Ralstonia metallidurans) (see paper)
51% identity, 99% coverage: 4:254/254 of query aligns to 40:299/299 of Q1LK00
- F68 (= F32) mutation to A: Abolishes catalytic activity.
- Y130 (= Y94) mutation to F: 15-fold increase in catalytic activity.
- R134 (= R98) mutation to A: Abolishes catalytic activity.
- T271 (= T226) mutation to A: Abolishes catalytic activity.
2noxB Crystal structure of tryptophan 2,3-dioxygenase from ralstonia metallidurans (see paper)
49% identity, 98% coverage: 4:252/254 of query aligns to 11:264/266 of 2noxB
- binding protoporphyrin ix containing fe: F39 (= F32), H43 (= H36), T46 (≠ K39), W90 (= W83), L93 (= L86), S112 (= S105), G113 (= G106), F114 (= F107), Y119 (≠ F112), R120 (= R113), H228 (= H212), V232 (= V216), E242 (≠ T226), Y246 (= Y234), L247 (= L235)
2nw9A Crystal structure of tryptophan 2,3-dioxygenase (tdo) from xanthomonas campestris in complex with ferrous heme and 6-fluoro-tryptophan. Northeast structural genomics target xcr13 (see paper)
42% identity, 98% coverage: 5:252/254 of query aligns to 3:261/265 of 2nw9A
- binding 6-fluoro-l-tryptophan: F32 (= F32), H36 (= H36), Y94 (= Y94), R98 (= R98), L101 (= L101), S104 (= S104), G234 (= G225), T235 (= T226)
- binding protoporphyrin ix containing fe: F32 (= F32), H36 (= H36), S39 (≠ K39), W83 (= W83), L86 (= L86), G106 (= G106), F107 (= F107), Y112 (≠ F112), R113 (= R113), H221 (= H212), V225 (= V216), I229 (= I220), G234 (= G225), G236 (= G227), S238 (≠ T229)
Q8PDA8 Tryptophan 2,3-dioxygenase; TDO; Tryptamin 2,3-dioxygenase; Tryptophan oxygenase; TO; TRPO; Tryptophan pyrrolase; Tryptophanase; EC 1.13.11.11 from Xanthomonas campestris pv. campestris (strain ATCC 33913 / DSM 3586 / NCPPB 528 / LMG 568 / P 25) (see 2 papers)
42% identity, 98% coverage: 5:252/254 of query aligns to 22:280/298 of Q8PDA8
- FIIQH 51:55 (≠ FVIIH 32:36) binding substrate
- H55 (= H36) mutation to A: Decrease in catalytic efficiency using L-tryptophan, 5-fluoro-D/L-tryptophan, 6-fluoro-D/L-tryptophan, 5-methyl-D/L-tryptophan and 6-methyl-D/L-tryptophan as substrate.; mutation to S: Decrease in catalytic efficiency using L-tryptophan, 5-fluoro-D/L-tryptophan, 6-fluoro-D/L-tryptophan, 5-methyl-D/L-tryptophan and 6-methyl-D/L-tryptophan as substrate.
- Y113 (= Y94) binding substrate
- R117 (= R98) binding substrate
- H240 (= H212) binding axial binding residue
- T254 (= T226) binding substrate
7p46A Crystal structure of xanthomonas campestris tryptophan 2,3-dioxygenase (tdo) (see paper)
42% identity, 98% coverage: 5:252/254 of query aligns to 18:276/281 of 7p46A
- binding protoporphyrin ix containing fe: S51 (≠ H36), S54 (≠ K39), W98 (= W83), S120 (= S105), G121 (= G106), F122 (= F107), Y127 (≠ F112), R128 (= R113), H236 (= H212), V240 (= V216), G249 (= G225), G251 (= G227), S253 (≠ T229)
- binding (2S)-2-amino-4-(2-aminophenyl)-4-oxobutanoic acid: F47 (= F32), S51 (≠ H36), Y109 (= Y94), R113 (= R98), S119 (= S104), G249 (= G225), T250 (= T226)
- binding tryptophan: K82 (= K67), A85 (= A70), Y216 (= Y192), S217 (≠ Q193), E220 (= E196), D224 (= D200)
1yw0A Crystal structure of the tryptophan 2,3-dioxygenase from xanthomonas campestris. Northeast structural genomics target xcr13.
38% identity, 97% coverage: 6:252/254 of query aligns to 1:239/243 of 1yw0A
6pyzC Crystal structure of human tryptophan 2,3-dioxygenase in complex with pf-06840003 in active site (see paper)
30% identity, 98% coverage: 5:254/254 of query aligns to 2:314/333 of 6pyzC
- binding (3S)-3-(5-fluoro-1H-indol-3-yl)pyrrolidine-2,5-dione: Y4 (= Y7), Y7 (= Y10), F34 (= F32), H38 (= H36), A112 (≠ S104), S113 (= S105), T284 (= T226)
- binding protoporphyrin ix containing fe: H38 (= H36), Y41 (≠ K39), L94 (= L86), G114 (= G106), F115 (= F107), F120 (= F112), R121 (= R113), H270 (= H212), M273 (≠ T215), V274 (= V216), M277 (≠ V219), G283 (= G225), G285 (= G227), S287 (≠ T229), Y292 (= Y234), L293 (= L235)
- binding alpha-methyl-L-tryptophan: R65 (vs. gap), E67 (vs. gap), W167 (= W141), R170 (≠ A144), T171 (≠ N145), P172 (≠ A146), F246 (≠ W188)
5ti9C Crystal structure of human tdo in complex with trp and dioxygen, northeast structural genomics consortium target hr6161 (see paper)
31% identity, 98% coverage: 5:254/254 of query aligns to 1:307/326 of 5ti9C
- binding protoporphyrin ix containing fe: H37 (= H36), Y40 (≠ K39), L93 (= L86), S112 (= S105), G113 (= G106), F114 (= F107), F119 (= F112), R120 (= R113), W259 (= W208), H263 (= H212), V267 (= V216), M270 (≠ V219), G276 (= G225), G278 (= G227), S280 (≠ T229), L286 (= L235)
- binding N'-Formylkynurenine: F33 (= F32), H37 (= H36), R105 (= R98), L108 (= L101), A111 (≠ S104), S112 (= S105), G113 (= G106), L271 (≠ I220), G276 (= G225), T277 (= T226)
- binding tryptophan: R64 (vs. gap), E66 (vs. gap), W159 (= W141), R162 (≠ A144), T163 (≠ N145), P164 (≠ A146), I230 (≠ V179), F239 (≠ W188), P242 (≠ L191)
6a4iD Crystal structure of human tdo inhibitor complex
31% identity, 98% coverage: 5:254/254 of query aligns to 1:275/290 of 6a4iD
- binding 1-(6-chloro-1H-indazol-4-yl)cyclohexan-1-ol: Y3 (= Y7), Y6 (= Y10), F33 (= F32), H37 (= H36), A111 (≠ S104)
- binding protoporphyrin ix containing fe: F33 (= F32), H37 (= H36), Y40 (≠ K39), F101 (≠ Y94), S112 (= S105), G113 (= G106), F114 (= F107), F119 (= F112), H239 (= H212), V243 (= V216), M246 (≠ V219), L254 (= L235)
- binding tryptophan: R64 (vs. gap), W153 (= W141), R156 (≠ A144), T157 (≠ N145), P158 (≠ A146), I206 (≠ V179), F215 (≠ W188)
6a4iB Crystal structure of human tdo inhibitor complex
30% identity, 98% coverage: 5:254/254 of query aligns to 1:295/309 of 6a4iB
- binding 1-(6-chloro-1H-indazol-4-yl)cyclohexan-1-ol: Y3 (= Y7), Y6 (= Y10), F33 (= F32), H37 (= H36), L108 (= L101), A111 (≠ S104)
- binding protoporphyrin ix containing fe: F33 (= F32), H37 (= H36), Y40 (≠ K39), L93 (= L86), S112 (= S105), G113 (= G106), F114 (= F107), F119 (= F112), R120 (= R113), W255 (= W208), H259 (= H212), V263 (= V216), L274 (= L235)
- binding tryptophan: R64 (vs. gap), E66 (vs. gap), W153 (= W141), R156 (≠ A144), T157 (≠ N145), P158 (≠ A146), P238 (≠ L191)
6a4iA Crystal structure of human tdo inhibitor complex
28% identity, 98% coverage: 5:254/254 of query aligns to 1:313/322 of 6a4iA
- binding 1-(6-chloro-1H-indazol-4-yl)cyclohexan-1-ol: Y3 (= Y7), Y6 (= Y10), F33 (= F32), H37 (= H36), A111 (≠ S104)
- binding protoporphyrin ix containing fe: F33 (= F32), H37 (= H36), Y40 (≠ K39), L93 (= L86), F101 (≠ Y94), S112 (= S105), G113 (= G106), F114 (= F107), F119 (= F112), W270 (= W208), H274 (= H212), M277 (≠ T215), V278 (= V216), M281 (≠ V219), L292 (= L235)
- binding tryptophan: R64 (vs. gap), W158 (= W141), R161 (≠ A144), T162 (≠ N145), P163 (≠ A146), I241 (vs. gap), F250 (≠ W188), P253 (≠ L191)
8vzvCCC Tryptophan 2,3-dioxygenase (see paper)
29% identity, 98% coverage: 5:254/254 of query aligns to 2:307/326 of 8vzvCCC
- binding 6-fluoro-3-[(E)-2-(1H-tetrazol-5-yl)ethenyl]-1H-indole: Y4 (= Y7), Y7 (= Y10)
- binding protoporphyrin ix containing fe: F34 (= F32), H38 (= H36), Y41 (≠ K39), L94 (= L86), S113 (= S105), G114 (= G106), F115 (= F107), F120 (= F112), R121 (= R113), W268 (= W208), H272 (= H212), M275 (≠ T215), V276 (= V216), M279 (≠ V219), L286 (= L235)
- binding alpha-methyl-L-tryptophan: R65 (vs. gap), E67 (vs. gap), W166 (= W141), R169 (≠ A144), T170 (≠ N145), P171 (≠ A146), F248 (≠ W188)
7lu7CCC Tryptophan 2,3-dioxygenase (see paper)
28% identity, 98% coverage: 5:254/254 of query aligns to 2:305/323 of 7lu7CCC
- binding (1~{R})-1-cyclohexyl-2-[(5~{S})-5~{H}-imidazo[1,5-b]isoindol-5-yl]ethanol: Y4 (= Y7), Y7 (= Y10), F34 (= F32), H38 (= H36), A112 (≠ S104), G114 (= G106)
- binding protoporphyrin ix containing fe: H38 (= H36), Y41 (≠ K39), S113 (= S105), G114 (= G106), F115 (= F107), F120 (= F112), R121 (= R113), W266 (= W208), H270 (= H212), V274 (= V216)
- binding alpha-methyl-L-tryptophan: R65 (vs. gap), E67 (vs. gap), W163 (= W141), R166 (≠ A144), T167 (≠ N145), P168 (≠ A146), F246 (≠ W188), P249 (≠ L191)
P20351 Tryptophan 2,3-dioxygenase; TDO; Protein vermilion; Tryptamin 2,3-dioxygenase; Tryptophan oxygenase; TO; TRPO; Tryptophan pyrrolase; Tryptophanase; EC 1.13.11.11 from Drosophila melanogaster (Fruit fly) (see paper)
46% identity, 45% coverage: 7:121/254 of query aligns to 27:151/379 of P20351
- D123 (= D93) mutation to A: Strongly reduced enzyme activity.
Sites not aligning to the query:
- 236 Y→F: Strongly reduced enzyme activity.
- 309 R→A: Strongly reduced enzyme activity.
- 312 binding axial binding residue
- 335 Y→F: Strongly reduced enzyme activity.
4hkaA Crystal structure of drosophila melanogaster tryptophan 2,3- dioxygenase in complex with heme (see paper)
46% identity, 45% coverage: 7:121/254 of query aligns to 4:128/345 of 4hkaA
Sites not aligning to the query:
Q09474 Tryptophan 2,3-dioxygenase; TDO; Tryptamin 2,3-dioxygenase; Tryptophan oxygenase; TO; TRPO; Tryptophan pyrrolase; Tryptophanase; EC 1.13.11.11 from Caenorhabditis elegans (see paper)
40% identity, 46% coverage: 6:122/254 of query aligns to 38:164/403 of Q09474
- PLD 133:135 (≠ PSD 91:93) PLD motif; required for enzymatic activity; mutation Missing: Abolishes catalytic activity. Animals have an extended lifespan, an extended reproductive lifespan, have fewer hatched progeny and display increased motility.
8r5qA Structure of apo tdo with a bound inhibitor (see paper)
34% identity, 58% coverage: 5:151/254 of query aligns to 1:158/314 of 8r5qA
- binding 3-chloranyl-~{N}-[(1~{S})-1-(6-chloranylpyridin-3-yl)-2-phenyl-ethyl]aniline: Y3 (= Y7), Y6 (= Y10), L7 (= L11), F33 (= F32), H37 (= H36), F101 (≠ Y94), P110 (≠ G103), G113 (= G106), F114 (= F107), Q115 (= Q108), S116 (= S109)
- binding alpha-methyl-L-tryptophan: R64 (vs. gap), E66 (vs. gap), W154 (≠ A147), R157 (= R150), T158 (≠ A151)
Sites not aligning to the query:
8r5qC Structure of apo tdo with a bound inhibitor (see paper)
37% identity, 47% coverage: 5:124/254 of query aligns to 1:131/317 of 8r5qC
- binding 3-chloranyl-~{N}-[(1~{S})-1-(6-chloranylpyridin-3-yl)-2-phenyl-ethyl]aniline: Y3 (= Y7), Y6 (= Y10), L7 (= L11), F33 (= F32), H37 (= H36), F101 (≠ Y94), P110 (≠ G103), G113 (= G106), Q115 (= Q108), S116 (= S109)
- binding alpha-methyl-L-tryptophan: R64 (vs. gap), E66 (vs. gap)
Sites not aligning to the query:
7lu7AAA Tryptophan 2,3-dioxygenase (see paper)
34% identity, 58% coverage: 5:152/254 of query aligns to 2:155/341 of 7lu7AAA
- binding (1~{R})-1-cyclohexyl-2-[(5~{S})-5~{H}-imidazo[1,5-b]isoindol-5-yl]ethanol: Y4 (= Y7), Y7 (= Y10), F34 (= F32), H38 (= H36), A112 (≠ S104), G114 (= G106)
- binding protoporphyrin ix containing fe: F34 (= F32), H38 (= H36), Y41 (≠ K39), L94 (= L86), S113 (= S105), G114 (= G106), F115 (= F107), F120 (= F112), R121 (= R113)
- binding alpha-methyl-L-tryptophan: R65 (vs. gap), E67 (vs. gap)
Sites not aligning to the query:
8vzvAAA Tryptophan 2,3-dioxygenase (see paper)
34% identity, 58% coverage: 5:152/254 of query aligns to 2:155/344 of 8vzvAAA
- binding 6-fluoro-3-[(E)-2-(1H-tetrazol-5-yl)ethenyl]-1H-indole: F34 (= F32), H38 (= H36), R106 (= R98), L109 (= L101), A112 (≠ S104), S113 (= S105)
- binding protoporphyrin ix containing fe: F34 (= F32), H38 (= H36), Y41 (≠ K39), L94 (= L86), S113 (= S105), G114 (= G106), F115 (= F107), F120 (= F112), R121 (= R113)
- binding alpha-methyl-L-tryptophan: R65 (vs. gap), E67 (vs. gap)
Sites not aligning to the query:
Query Sequence
>Ga0059261_1376 FitnessBrowser__Korea:Ga0059261_1376
MSDDMTYGRYLALDQLLSAQHPISDEHDELLFVIIHQTKELWLKQAIAELRVALDLVRND
KLVEAYKSLARVSRIQAVMTLSWEVLTTMTPSDYSAFRSVLGGSSGFQSDQFRAVETLLG
LRGGGVPGPLTTEFAALPSLWDEANAALARADFDLPETALNRDWSKPYQPSPEVEAAWVQ
VYRDPHRWWELYQLAEKLVDIDDALATWRHKHVLTVSRVIGMKPGTGGTPGVPYLQSTVA
KRAFPELWSLRTLL
Or try a new SitesBLAST search
SitesBLAST's Database
SitesBLAST's database includes
(1) SwissProt
entries with experimentally-supported functional features;
and (2) protein structures with bound ligands, from the
BioLip database.
by Morgan Price,
Arkin group
Lawrence Berkeley National Laboratory